8-K: EyePoint Pharmaceuticals Reports Positive DURAVYU Trial Results and Financial Update

EyePoint Pharmaceuticals announces positive Phase 2 VERONA trial results for DURAVYU in DME and provides a financial update, highlighting a strong cash position and progress in Phase 3 wet AMD trials.

Summary

• EyePoint Pharmaceuticals reported its fourth quarter and full-year 2024 financial results.
• The company highlighted positive developments in its DURAVYU clinical programs.
• Enrollment in the Phase 3 LUGANO and LUCIA trials for wet AMD is exceeding expectations, with LUGANO over 50% enrolled.
• Topline data from these trials is expected in 2026.
• The Phase 2 VERONA trial of DURAVYU for DME met its primary and secondary endpoints, showing improvement in BCVA and CST.
• Total net revenue for Q4 2024 was $11.6 million, compared to $14.0 million in Q4 2023.
• Total net revenue for the full year 2024 was $43.3 million, compared to $46.0 million in 2023.
• The company had $371 million in cash and investments as of December 31, 2024, which is expected to fund operations into 2027.
• EyePoint does not plan to access equity capital markets in 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the positive clinical trial results and strong cash position, but tempered by the decrease in revenue and increased net loss.

Positives

• Enrollment in DURAVYU Phase 3 wet AMD trials is exceeding expectations.
• The Phase 2 VERONA trial of DURAVYU for DME showed positive results, meeting primary and secondary endpoints.
• The company has a strong cash position of $371 million, providing a cash runway into 2027.
• Positive 24-week supplement-free patient subgroup analyses from the Phase 2 VERONA clinical trial in DME demonstrated that DURAVYU 2.7mg significantly improved vision and fluid versus baseline compared to the aflibercept control group.

Negatives

• Total net revenue decreased in both Q4 2024 and full-year 2024 compared to the previous year.
• Net product revenue decreased for the full year 2024 due to the license of YUTIQ product rights.
• Operating expenses increased significantly due to the ongoing Phase 3 trials for DURAVYU and increased personnel costs.
• Net loss increased to $41.4 million in Q4 2024 and $130.9 million for the full year 2024.

Risks

• The timing, progress, and results of clinical development activities are uncertain.
• Clinical trials may face delays and unexpected costs.
• Clinical trial results may not be predictive of future results.
• Unexpected safety or efficacy data may be observed during clinical trials.
• The regulatory authorization or approval process is uncertain.
• Changes in the regulatory environment or competition could impact the company.
• The company depends on contract research organizations and other outside vendors.
• The company may need additional financing in the future.

Future Outlook

EyePoint expects its current cash and investments to fund operations into 2027, beyond the topline Phase 3 data for DURAVYU in wet AMD expected in 2026, and currently has no plans to access the equity capital markets in 2025.

Management Comments

• Jay Duker, M.D., President and Chief Executive Officer of EyePoint, stated that the company is off to a strong start in 2025, advancing DURAVYU across clinical programs in wet AMD and DME.
• He noted that enrollment in the LUGANO and LUCIA Phase 3 clinical trials in wet AMD continues to exceed expectations.
• He expressed confidence in DURAVYU's potential as a blockbuster drug poised to potentially redefine the treatment paradigm in two prevalent diseases.

Industry Context

EyePoint is focused on developing sustained delivery therapies for retinal diseases, a competitive area with companies like Roche (Vabysmo), Regeneron (Eylea), and Novartis (Beovu) also developing treatments for wet AMD and DME. EyePoint's DURAVYU aims to differentiate itself through its sustained-release TKI profile and potential for less frequent dosing.

Comparison to Industry Standards

• The LUGANO trial is over 50% enrolled, significantly exceeding observed historical enrollment rates of both comparable and competitive wet AMD trials.
• The VERONA trial results are being compared to aflibercept (Eylea) as a control, demonstrating DURAVYU's potential to provide an immediate benefit over this established treatment.
• The company is positioning DURAVYU as a potential competitor to existing treatments like Eylea, Vabysmo and Beovu, with the goal of reducing treatment burden and improving patient outcomes.

Management Changes

Stakeholder Impact

• Shareholders: Positive clinical trial results and strong cash position could increase shareholder value.
• Patients: DURAVYU has the potential to improve treatment outcomes and reduce treatment burden for patients with wet AMD and DME.
• Employees: Continued progress and financial stability could improve employee morale and job security.
• Customers: The company does not have any customers as it has exited its commercial business.

Next Steps

• Complete enrollment of LUGANO and LUCIA trials in the second half of 2025.
• Report topline data from LUGANO and LUCIA trials in 2026.
• Meet with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program based on VERONA trial results.
• Continue clinical development of other product candidates, including EYP-2301.

Key Dates